In last trading session, ProMIS Neurosciences Inc (NASDAQ:PMN) saw 1.28 million shares changing hands with its beta currently measuring -0.08. Company’s recent per share price level of $0.45 trading at $0.01 or 2.27% at ring of the bell on the day assigns it a market valuation of $14.71M. That closing price of PMN’s stock is at a discount of -393.33% from its 52-week high price of $2.22 and is indicating a premium of 15.56% from its 52-week low price of $0.38. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 9.81 million shares which gives us an average trading volume of 1.70 million if we extend that period to 3-months.
ProMIS Neurosciences Inc (NASDAQ:PMN) trade information
Upright in the green during last session for gaining 2.27%, in the last five days PMN remained trading in the green while hitting it’s week-highest on Monday, 07/14/25 when the stock touched $0.45 price level, adding 64.0% to its value on the day. ProMIS Neurosciences Inc’s shares saw a change of -78.67% in year-to-date performance and have moved 14.77% in past 5-day. ProMIS Neurosciences Inc (NASDAQ:PMN) showed a performance of -13.38% in past 30-days. Number of shares sold short was 0.14 million shares which calculate 3.01 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 4 to the stock, which implies a rise of 88.75% to its current value. Analysts have been projecting 4 as a low price target for the stock while placing it at a high target of 4. It follows that stock’s current price would drop -788.89% in reaching the projected high whereas dropping to the targeted low would mean a loss of -788.89% for stock’s current value.
ProMIS Neurosciences Inc (NASDAQ:PMN)’s Major holders
Insiders are in possession of 27.61% of company’s total shares while institution are holding 28.56 percent of that, with stock having share float percentage of 39.45%. Investors also watch the number of corporate investors in a company very closely, which is 28.56% institutions for ProMIS Neurosciences Inc that are currently holding shares of the company.
